CA3226836A1 - Method of treating veterinary viral diseases - Google Patents
Method of treating veterinary viral diseases Download PDFInfo
- Publication number
- CA3226836A1 CA3226836A1 CA3226836A CA3226836A CA3226836A1 CA 3226836 A1 CA3226836 A1 CA 3226836A1 CA 3226836 A CA3226836 A CA 3226836A CA 3226836 A CA3226836 A CA 3226836A CA 3226836 A1 CA3226836 A1 CA 3226836A1
- Authority
- CA
- Canada
- Prior art keywords
- animal
- virus
- days
- feline
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21190172 | 2021-08-06 | ||
| EP21190172.3 | 2021-08-06 | ||
| EP22185716 | 2022-07-19 | ||
| EP22185716.2 | 2022-07-19 | ||
| PCT/EP2022/072074 WO2023012329A1 (en) | 2021-08-06 | 2022-08-05 | Method of treating veterinary viral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226836A1 true CA3226836A1 (en) | 2023-02-09 |
Family
ID=83151800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226836A Pending CA3226836A1 (en) | 2021-08-06 | 2022-08-05 | Method of treating veterinary viral diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240342204A1 (https=) |
| EP (1) | EP4380578A1 (https=) |
| JP (1) | JP2024528237A (https=) |
| AU (1) | AU2022323465A1 (https=) |
| BR (1) | BR112024002195A2 (https=) |
| CA (1) | CA3226836A1 (https=) |
| MX (1) | MX2024001645A (https=) |
| WO (1) | WO2023012329A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5030587B2 (ja) | 2003-06-26 | 2012-09-19 | バイオトロン・リミテッド | 抗ウイルスアシルグアニジン化合物および方法 |
| NZ615939A (en) | 2011-05-10 | 2015-04-24 | Aratana Therapeutics Nv | Compounds for use in the treatment of feline retroviral infections |
| GB201203180D0 (en) | 2012-02-24 | 2012-04-11 | Okapi Sciences Nv | Compounds for treating parvovirus infection |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| KR20200140274A (ko) | 2018-03-07 | 2020-12-15 | 에모리 유니버시티 | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 |
-
2022
- 2022-08-05 CA CA3226836A patent/CA3226836A1/en active Pending
- 2022-08-05 JP JP2024506795A patent/JP2024528237A/ja active Pending
- 2022-08-05 US US18/294,592 patent/US20240342204A1/en active Pending
- 2022-08-05 WO PCT/EP2022/072074 patent/WO2023012329A1/en not_active Ceased
- 2022-08-05 AU AU2022323465A patent/AU2022323465A1/en active Pending
- 2022-08-05 BR BR112024002195A patent/BR112024002195A2/pt unknown
- 2022-08-05 EP EP22762011.9A patent/EP4380578A1/en active Pending
- 2022-08-05 MX MX2024001645A patent/MX2024001645A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023012329A1 (en) | 2023-02-09 |
| JP2024528237A (ja) | 2024-07-26 |
| US20240342204A1 (en) | 2024-10-17 |
| AU2022323465A1 (en) | 2024-02-01 |
| MX2024001645A (es) | 2024-02-27 |
| EP4380578A1 (en) | 2024-06-12 |
| BR112024002195A2 (pt) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Higgins et al. | The equine manual E-book: the equine manual E-book | |
| Johnson | Fueling the immune response: what’s the cost? | |
| JP2017525681A (ja) | パラミクソウイルスの治療方法 | |
| US20240342204A1 (en) | Method of treating veterinary viral diseases | |
| ES2877808T3 (es) | Producto combinado para tratar o mejorar una infección por virus respiratorio sincicial | |
| KR101929141B1 (ko) | 돼지 사료에서의 나라신의 항바이러스 효과 | |
| KR20160093046A (ko) | 로소니아 인트라셀룰라리스 및 돼지 써코바이러스 2에 대한 백신 | |
| Pastoret et al. | Veterinary vaccines for animal and public health | |
| EP1140103B1 (en) | Ponazuril for treating neurologic and abortigenic diseases caused by coccidia. | |
| TW201731526A (zh) | 混成核心之貓科動物疫苗 | |
| JP7293225B2 (ja) | 組合せ製品を用いるｒｓｖの処置 | |
| CN117858710A (zh) | 治疗兽医学病毒性疾病的方法 | |
| RU2546247C2 (ru) | Вакцина против чумы, аденовирусных инфекций, парвовирусного и коронавирусного энтеритов, лептоспироза и бешенства собак | |
| CN102869380A (zh) | 用于禽舍疾病的活疫苗 | |
| US6429211B1 (en) | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora | |
| JP2024529291A (ja) | ウイルス感染症の処置および予防のための組成物および方法 | |
| Crawford et al. | Efficacy of ivermectin administration to growing pigs after a virulent porcine reproductive and respiratory syndrome virus 1-4-4 L1C challenge | |
| CN114901293A (zh) | 用于预防或治疗幼小的哺乳动物得与黏膜相关的传染性疾病的血清组成物的制造方法、通过该方法制造的血清组成物及其用途 | |
| RU2292220C1 (ru) | Способ профилактики инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота | |
| Kirkland et al. | Paramyxoviruses: rubulavirus, Menangle, and Nipah virus infections | |
| KR102065848B1 (ko) | 엔테로코코스 카니테스티니(Enterococcus canintestini)균주를 함유하는 항인플루엔자 바이러스 조성물 | |
| Jaramillo | Immune Response and Protection Against BVDV-2 and BHV-1 Infection Elicited by Modified-Live Virus Vaccination in Dairy Calves. Effects of Vaccination Route and Trace Mineral Injection | |
| WO2024097158A1 (en) | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | |
| Rout | Carrier state in domestic and wildlife species: a debatable issue of concern in the epidemiology of foot-and-mouth disease | |
| RU2308269C1 (ru) | Способ профилактики вирусной диареи - болезни слизистых крупного рогатого скота у телят при помощи противовирусного препарата йодантипирин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241119 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250319 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250422 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250709 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250709 |